One contribution of 13 to a discussion meeting issue 'Extracellular vesicles and the tumour microenvironment'. Ovarian cancer has a poor overall survival that is partly caused by resistance to drugs such as cisplatin. Resistance can be acquired as a result of changes to the tumour or due to altered interactions within the tumour microenvironment. Extracellular vesicles (EVs), small lipid-bound vesicles that are loaded with macromolecular cargo and released by cells, are emerging as mediators of communication in the tumour microenvironment. We previously showed that EVs mediate the bystander effect, a phenomenon in which stressed cells can communicate with neighbouring naive cells leading to various effects including DNA damage; however, the role of EVs released following cisplatin treatment has not been tested. Here we show that treatment of cells with cisplatin led to the release of EVs that could induce invasion and increased resistance when taken up by bystander cells. This coincided with changes in p38 and JNK signalling, suggesting that these pathways may be involved in mediating the effects. We also show that EV uptake inhibitors could prevent this EV-mediated adaptive response and thus sensitize cells in vitro to the effects of cisplatin. Our results suggest that preventing pro-tumourigenic EV cross-talk during chemotherapy is a potential therapeutic target for improving outcome in ovarian cancer patients.
Introduction
Ovarian cancer is the most fatal gynaecological cancer, with more than 150 000 women succumbing to the disease each year worldwide [1] . The 5-year survival rate is less than 50% [2] . Reasons for this high mortality rate include diagnosis at advanced stages and acquired resistance to chemotherapeutic drugs such as cisplatin and carboplatin [3] [4] [5] . The causes for cisplatin resistance are complex and multifactorial [6] [7] [8] [9] . Along with numerous intracellular modulators, intercellular factors involving the tumour microenvironment have also been shown to play a crucial role in cisplatin resistance; this can occur via altered communication between tumour cells and stromal cells [10] , macrophages [11] or endothelial cells [12] as well as between tumour cells [13, 14] .
In recent years, exosomes and microvesicles (collectively referred to as extracellular vesicles (EVs)) have gained prominence as mediators of intercellular communication. They have been shown to transfer RNAs and proteins that are functional in the recipient cells [15, 16] . They can be found in various & 2017 The Author(s) Published by the Royal Society. All rights reserved.
body fluids and in the tumour microenvironment and can transmit messages to neighbouring cells as well as to distant cells [17, 18] . miRNAs, short non-coding RNAs whose levels can be altered during stress response [19] , can also be shuttled between cells in the tumour microenvironment via EVs. EVs have been shown to modulate numerous factors in tumour cells including proliferation [20] , viability [21] and metastatic capability [22] . The tumour microenvironment has also been shown to be modulated by EV-mediated communication between the tumour and other cells such as cancer associated fibroblasts [23, 24] and mesenchymal stem cells [25] . EVs are able to modulate angiogenesis, an important factor in cancer progression [26] [27] [28] [29] . EVs have also been shown to modulate the anti-tumoral response by affecting the immune response, T-cell activation and natural killer cell induction [30 -33] . EVs can also contribute to drug resistance via various mechanisms, including the sequestration of drugs [34, 35] and the transfer of proteins or RNA [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . The morphology and the proteomic profile of EVs from multi-drug resistant tumours have been shown to be different from those from sensitive tumours [46] and EVs could be used as prognostic and diagnostic biomarkers in cancer [47] .
Interestingly, EVs are involved in bystander effect (BE) [48] . BE is a phenomenon in which stressed cells release soluble factors that when taken up by naive recipient cells can induce phenotypic effects, including DNA damage [48] [49] [50] [51] [52] [53] . The potential roles for EVs released from cisplatin-stressed ovarian cancer cells, particularly in the context of the tumour microenvironment, have not been investigated. Here we show that chemotherapeutic treatment of ovarian tumour cells induces the release of EVs that can influence the phenotype of neighbouring naive cells. Specifically, we show that the EVs released following cisplatin-stress response can induce increased invasiveness and drug resistance in bystander cells. These effects coincided with changes in signalling via several pathways including p38 and JNK. Blocking the uptake of EVs during cisplatin treatment appeared to sensitize cells to the effect of the cytotoxic drug. Taken together these results suggest that EVs released by cells into the tumour microenvironment during chemotherapy could have an important role in mediating the progression of ovarian cancer.
Material and methods (a) Cell culture
All cell lines were maintained in RPMI media (Hyclone) supplemented with 10% fetal bovine serum (Gibco) and sub-cultured every 5-6 d using 0.05% trypsin with EDTA (Thermo Fisher Scientific). Cells were maintained at 378C in a humidified incubator at 5% CO 2 ; fresh media was added every 2-3 d. A2780 and CP70 were kindly donated by Professor Robert Brown (University College London). IGROV-1 cells were purchased from National Cancer Institute, Frederick Cancer Division of Cancer Treatment and Diagnosis Tumor/Cell Line Repository (Bethesda, USA).
(b) Extracellular vesicle extraction
Fetal bovine serum was ultracentrifuged at 120 000g for 16 h; RPMI or DMEM was then supplemented with 10% EV-depleted bovine serum to obtain EV-depleted media (EDM). Cells in T175 flasks at 70 -80% confluence (approx. 2.0 Â 10 7 ) were grown overnight in EDM. For cisplatin treatments, cells at 70% confluence were treated with a final concentration of 40 mM cisplatin for 2 h at 378C, cisplatincontaining media was removed, cells were washed with PBS, replenished with EDM and incubated for a further 2 h. After this time, media was removed to eliminate any cisplatin secreted by the treated cells and replenished with fresh EDM and this media was conditioned for 24 h. EVs were extracted from this conditioned medium by differential ultracentrifugation. Initially, it was centrifuged at 300g for 5 min followed by centrifugation at 16 500g for 20 min at 48C. The media was then filtered using 0.22 mm syringe filters blocked with 0.1% bovine serum albumin (BSA) (Sigma Aldrich). The supernatant was ultracentrifuged at 120 000g using a Beckman Coulter Optima LE80 K ultracentrifuge for 90 min at 48C to pellet EVs. The extracted EVs were resuspended in PBS, and finally pelleted once more at 120 000g. EVs were resuspended in 50 ml PBS and used in subsequent experimentation. When not used immediately after extraction EVs were stored at 2808C.
(i) Western blotting of whole cell and extracellular vesicle protein extracts
Cells were scraped from the surface of a culture flask into ice cold PBS and pelleted at 300g, washed with PBS and re-pelleted at 300g. Cell preparations were then lysed in 1 Â radioimmunoprecipitation assay (RIPA) buffer (0. (ii) Transmission electron microscopy of extracellular vesicle samples A 12 ml aliquot of each EV sample was combined with an equal volume of 4% paraformaldehyde (Sigma Aldrich) and incubated on ice for 15 min. A droplet of each sample was distributed using a pipette onto Parafilm (Thermo Fisher Scientific). Carbonformvar coated copper 300 mesh grids (Agar Scientific, Stanstead) were placed dullside downwards onto each sample droplet and left to incubate at RT for 30 min. Grids were then washed three times by placing dullside downwards onto a droplet of 0.22 mm filtered ultrapure water. Between each wash, excess water was removed using filter paper. Finally, each grid was placed onto a 30 ml droplet of 2% uranyl acetate (aqueous) (Sigma Aldrich) for 2 min. Excess solution was removed using filter paper and the samples were left to air dry for 60 min. Two grids were prepared from each aliquot. Grids were visualized using Hitachi H7650 Transmission Electron Microscope at 100 kV with Â40 000 magnification. EV diameter was measured using the measurement function in AMT software (Advanced Microscopy Techniques, Massachusetts, USA (iv) Matrigel transwell cell invasion assay A2780 or IGROV-1 cells were treated with EVs extracted from cisplatin-treated cells or untreated cells and starved of serum for 24 h prior to seeding in transwell inserts. The cells were harvested by trypsinization and seeded at 100 000 cells/well in Matrigelcoated 8 mm pore membrane transwell inserts (BD Biosciences); a second dose of EVs was added into the respective wells at the same time. Complete medium supplemented with 10% FBS was loaded in the receiver wells to act as a chemoattractant. Cells were then incubated at 378C for 24 h. The media was then removed from the inserts and the upper surface of the inserts swabbed with a cotton bud to remove any cells that had not invaded the membrane. The inserts were then washed with PBS and stained with 1% crystal violet (Sigma Aldrich) for 10 min, washed again with distilled water and mounted onto glass slides using diNbutyle phthalate in xylene (DEPEX) and glass coverslips. The membranes were visualized using a Zeiss Axioplan inverted microscope using Â125 magnification in differential interference contrast and all the cells were counted. Three hours after commencement of cisplatin treatment, the media containing cisplatin was removed, cells were washed with PBS and fresh media was added; heparin treatment was continued for cells in the heparin-treatment group. On day 4, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed as previously described [54, 55] to assess the viability of the cells in each group.
(d) Effect of extracellular vesicle uptake inhibitors on cisplatin response
Cells were seeded in 96 well plates at 6000, 10 000 and 15 000 cells per well for CP70, A2780 and IGROV-1 cells, respectively; 48 h later, cells were pre-treated with EV uptake inhibitor as follows. Heparin (Sigma Aldrich, H3393) was diluted to a concentration of 10 mg ml 21 in deionized distilled water, filtered through 0.22 mm filters and stored at 2208C; it was diluted in media and added to cells at a final concentration of 10 mg ml
21
. Amiloride (5-(N-ethyl-N-isopropyl) amiloride, or EIPA) (Sigma Aldrich, A3085) was stored in DMSO at a concentration of 108 mM and added to cells at 50 mM concentration. Dynasore (Sigma, D7693) was diluted in DMSO to a concentration of 31 mM, stored at 2208C and added to cells at a concentration of 50 mM; 30 min after the drug treatment, cisplatin was added at varying concentrations to give a cisplatin response curve. Three hours later, cisplatin was removed, cells were washed with PBS and fresh media added; inhibitors were added to the same wells as before. An MTT assay was carried out 48 h after cisplatin treatment to assess the viability of cells in each group.
(i) Xenograft experiments
Xenograft experiments were carried out at the animal testing facility at Queen's University, Belfast by Professor Helen McCarthy; A2780 s for this experiment were kindly provided by Dr Fiona Furlong, Queen's University, Belfast. Five million A2780 cells in matrigel were implanted subcutaneously into the flanks of BALB/c SCID mice. Animals were monitored regularly and body weights were measured three times a week. Tumour volume was calculated using the formula
where r is half of the geometric mean diameter (GMD), calculated as:
Treatment was started when the tumour measured 100 mm 3 . Twenty-four mice were then divided into four treatment groups: (i) cisplatin 5 mg kg 21 once weekly i.p., (ii) heparin (Sigma, H3393) only-10 mg kg 21 every day i.p., (iii) combination group-cisplatin 5 mg kg 21 once weekly i.p. and heparin 10 mg kg 21 once daily i.p. and (iv) control group. Tumour volume was monitored three times a week; when the tumour quadrupled in size, the animal was sacrificed. Any mice that lost 20% of body weight during the experiment were sacrificed as the treatment was deemed too toxic. All animal experiments were performed in adherence to our home office licence (PPL2678).
(
ii) Statistical analysis
The Student's t-test was used to determine statistical significance unless otherwise stated. GraphPad Prism was used to calculate IC50s for curves and to analyse significance in differences between IC50s of curves using the extra sum-of-squares F-test. For all experiments, at least three biological replicates for each point were performed to enable statistical comparisons. p-Values in figures are depicted as follows: *,0.05, **,0.01, ***,0.001.
Results and discussion (a) Characteristics of extracellular vesicles from control and cisplatin-treated cells
As a first step in assessing the role of EVs in the tumour microenvironment following drug treatment, we compared the characteristics of EVs from control cells (control EVs) and those from cells treated with cisplatin (cisplatin EVs).
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EVs were extracted by ultracentrifugation of media conditioned overnight with A2780 control cells or A2780 cells treated with cisplatin. Western blotting (figure 1a) confirmed the presence of GAPDH and HSP70, which are known to be present in EVs; the absence of calnexin and cytochrome c oxidase in both EV pellets established the absence of cellular contamination in the EV preparations. Total particle number was estimated by nanoparticle tracking analysis. There was no significant difference between the concentration of control EVs (13.0 Â 10 8 particles ml types of stress [49,56 -58] ; however, in our hands we observe small but non-significant increases in EV release following cisplatin (this work) and heat stress [59] . This discrepancy could be due to experimental difference such as doses of treatment or the period of EV conditioning. Nevertheless, our results confirm the presence of EVs released by cancer cells following treatment.
To further characterize EVs from the tumour cells, we performed transmission electron microscopy (TEM). TEM of the EVs from both control and cisplatin-treated cells showed vesicles of the expected size and morphology (figure 1c), with diameters ranging from 30 to 160 nm; however, the mean diameter of the cisplatin EVs (49.3 nm) was significantly smaller than that of the control EVs (87.6 nm) (Student's t-test p ¼ 2.1 Â 10 28 ) (figure 1d). Interestingly, we also find that TEM measurements of EVs released following heat [59] are smaller compared with those released under normal conditions. That the imaged EVs from stressed cells appear smaller could represent a genuine difference in size, or could represent a different biophysical property that causes an artefact of preparation in the TEM that leads to the EVs appearing smaller. Nevertheless, the results suggest there are qualitative differences between EVs that are released following cisplatin treatment, and are consistent with studies that have also demonstrated differences in the content of EVs that are released under conditions of stress [57, 58, [60] [61] [62] . Various studies have shown that EVs can induce an invasive and motile phenotype in recipient cells [63] [64] [65] . Our results suggest that, at least in the case of A2780 and IGROV-1 cells, the EVs released under normal conditions cannot induce greater levels of invasion when added to cells. However, the qualitative changes in EVs induced by cisplatin treatment confer the ability to induce greater invasion. Interestingly, our previously published data show that EVs released following heat stress can also induce greater invasion in recipient cells [59] , and others have shown that EVs released following exposure of cells to ionizing radiation can induce increased metastatic ability [57] . These results suggest that the release of EVs with the ability to induce invasiveness in recipient cells may be part of a more general intercellular response to stress that could be occurring in the tumour microenvironment.
(c) Cisplatin extracellular vesicles can cause bystander effect and an adaptive response to cisplatin
The BE is a phenomenon in which stressed cells can communicate with other cells, leading to apparently detrimental effects such as DNA damage in these bystander cells [48 -50,52,53,66] . Our recent work showed that EVs mediate BE following irradiation [48, 67] . Subsequent findings have confirmed that EVs mediate BE following different stresses, including radiation [48, 49, 67] and heat shock [59] . We therefore hypothesized that cancer cells stressed by the addition of cytotoxic chemotherapeutics could release EVs into the tumour microenvironment, which could then be taken up by other cells (including other cancer cells), leading to potential effects on tumour progression. To test the hypothesis that EVs released by stressed ovarian cancer cells could modulate the activity of bystander cells, we studied the effect of cisplatin on A2780 cells. EVs derived from cisplatin-treated cells appear to decrease the viability of bystander A2780 cells by 10% compared to cells treated with EVs from unstressed cells ( p ¼ 0.027) (figure 3a). Heparin has been shown to inhibit uptake of EVs [68, 69] . Treating bystander cells with heparin, which in our hands also inhibits EV uptake by more than 95% (data not shown), abrogates the ability of cisplatin-EVs to mediate BE ( figure 3a) . These results are consistent with previous findings showing that cytotoxic agents including mitomycin C [53, 66, 70] , bleomycin [66, 71] and vincristine [53] can induce BE. Our findings, which to our knowledge are the first to reveal an EV-mediated BE induced by cisplatin, support the hypothesis that a wide range of stressors can induce the release of EVs into the tumour microenvironment that can potentially modulate an intercellular stress response in a tumour.
The BE has been observed in several species, suggesting it provides a beneficial effect that has been conserved through evolution [72] [73] [74] . One consequence of BE is an adaptive response that renders bystander cells more resistant to future stressors [52] . Indeed, we have observed that bystander cells that take up EVs released from heat-shocked cells are more resistant to a repeated dose of heat shock [59] . To test whether a similar effect occurs in ovarian cancer cells following treatment with chemotherapeutics, we performed EV-mediated BE as described above, treated these bystander cells with a dose of cisplatin and by performing an MTT assay on these cells, we effectively measured the effect of EV treatment on their resistance to cisplatin. When cells were pre-treated with cisplatin-EVs and then challenged with cisplatin, they were significantly protected compared with cells pre-treated with PBS ( figure 3b ). This protective effect was reduced (but not completely abrogated, p ¼ 0.052) when the cells were also treated with heparin to block the uptake of the EVs (figure 3b). The observation that heparin does not completely block this adaptive response could either be because additional non-vesicular factors are required for the response, or because some of the effects could be mediated by interaction of the EV with receptors at the cell surface without the need for EV uptake and cargo delivery. A recent study has also demonstrated that EVs released following treatment of pancreatic cancer cells with gemcitabine can induce an adaptive response in recipient cells, which may be mediated by enhanced reactive oxygen species detoxification and miR-155-induced suppression of a gemcitabine metabolizing enzyme [75] . Taken together, our results are consistent with the hypothesis that treatment of cells with cisplatin-EVs induces a survival mechanism that allows them to adapt to resist the effects of cisplatin.
(d) Pathways differentially modulated by cisplatin extracellular vesicles in cells
To investigate the potential mechanisms by which cisplatinEVs induce bystander effects (including increased invasiveness and the adaptive response), we analysed changes in phosphorylation status of important signalling proteins. A2780 cells were treated with cisplatin EVs or control EVs, proteins were extracted and changes in phosphorylation were measured using a PhosphoMAPK array (figure 4). Seven proteins had significantly different relative levels of phosphorylation between the cells treated with cisplatin EVs compared with control EV. CREB ( p ¼ 0.019), extracellular signalregulated kinases (ERK) 2 ( p ¼ 0.050) and TOR ( p ¼ 0.0021) kinases were downregulated in A2780s treated with cisplatin EVs, while JNK2 ( p ¼ 0.00087), JNKpan ( p ¼ 0.044), p38a ( p ¼ 0.038) and p53 ( p ¼ 0.015) were upregulated. These results suggest the involvement of these pathways in the effects specifically mediated by cisplatin EVs, some of which are consistent with previously implicated roles in cisplatin resistance. Knockdown of p38, for example, can lead to increased sensitivity to cisplatin [76] , suggesting that the activation of p38 we observe in our cells could lead to increased resistance and therefore an adaptive response. JNK signalling is known to be involved in stress response and JNK phosphorylation is activated by a variety of stressors [77] . In the context of cisplatin treatment, JNK may be a 'double-edged sword', in that it can have pro-apoptotic effects but can also be associated cisplatin resistance [78] . These context-dependent effects may explain the observation that bystander cells appear to be simultaneously more stressed and more protected against future stress. Interestingly, JNK activation can also enhance the invasive and migratory behaviour of cells [79] , suggesting that this may also underlie our observation that EVs released following cisplatin-mediated stress induce greater invasion. Additional experiments are needed to elucidate whether delivery of vesicular cargo is required, whether signalling changes are responsible for the increased invasion and whether increased vesicular delivery of matrix metalloproteinases to the extracellular environment is an important factor. Taken together, our results suggest that changes in signalling activity are associated with the range of EV-mediated bystander effects observed following cisplatin treatment. Further work is needed to assess whether these effects occur within the tumour microenvironment and how these could contribute to tumour progression in vivo.
(e) Extracellular vesicle uptake inhibitors sensitize cells to cisplatin
The results above indicate that EVs released by cisplatin-treated cells can induce an adaptive response in bystander cells.
When treating a population of cells with cisplatin it would be difficult to disentangle the direct effect of the drug from any bystander effects that may be occurring; nevertheless, we reasoned that when such a cohort of cells is undergoing stress the transfer of cisplatin-EVs will occur, which could lead to the invasive and adaptive response we observe in bystander cells. If this is the case then the EV-mediated communication during cisplatin treatment would help the population to become more resistant to the drug. We therefore hypothesized that inhibiting this communication using heparin as an EV uptake blocker should prevent the adaptive response and thus sensitize the cells to the effects of cisplatin. To test this hypothesis, ovarian cancer cell lines were treated with EV uptake inhibitors and cisplatin and the effects on overall survival were measured using the MTT assay. Treatment of cells with heparin alone did not reduce overall survival of cells (data not shown), suggesting that heparin itself was not toxic at the doses used. Interestingly, pretreatment of cells with heparin significantly decreased the IC50 of A2780 cells from 31.3 to 21.2 mM (p , 0.0001) (figure 5a). Similar results were obtained in IGROV-1 (figure 5b) and CP70 (figure 5c) cell lines, with the IC50 decreasing from 60.4 and 146.8 mM to 52.6 and 118.9 mM, respectively ( p , 0.0001). To test whether other EV uptake inhibitors also have the same cisplatin-sensitizing effect we used amiloride and dynasore, which inhibit micropinocytosis and dynamin-requiring uptake pathways, respectively [80] . As expected, amiloride and dynasore both significantly sensitized A2780 cells to cisplatin (figure 5d). These results suggest that blocking EV transfer between cells in the tumour microenvironment during chemotherapy could lead to more effective killing of cancer cells. Interestingly, heparin has previously been shown to increase sensitivity to cisplatin. In a recent study, it was shown that tinzaparin, a low-molecular weight heparin, was shown to sensitize A2780 cells to cisplatin; cell surface heparan sulfate proteoglycans were shown to be involved [81] . Heparin has also been shown to decrease invasion and migration in breast and lung cancer cell lines [82] [83] [84] . Heparin was also shown to increase cytotoxicity caused by chemotherapeutic drugs in breast cancer cells; an effect on drug efflux transporters ABCG2 and ABCC1 was noted that led to increasing levels of cytotoxic drugs within cells [85] . Our results suggest that the sensitizing effect of heparin may be at least in part due to inhibiting the EV-mediated cross-talk between cells during treatment.
(f ) Heparin does not appear to increase cisplatin sensitivity in vivo
The finding that treating ovarian cancer cells with heparin sensitizes them to cisplatin has obvious therapeutic implications.
To test whether heparin could sensitize ovarian cancer cells in vivo we used a xenograft model. A2780 cells were implanted subcutaneously in the flank of BALB/c SCID mice. The mice were then assigned to one of four groups (i) control, (ii) cisplatin treatment only, (iii) heparin treatment only, and (iv) heparin and cisplatin treatment; tumour volume was regularly monitored to test the effect of treatment on tumour progression. Tumour doubling-time, volume and survival are shown in figure 6a-c, respectively. Contrary to our expectations, heparin when given alongside cisplatin did not slow the growth of the tumour nor did it decrease the survival. Indeed, the addition of heparin appeared to speed up doubling-time compared to adding cisplatin alone. Thus, it appears from this experiment that either heparin does not have the same effect on EV communication in vivo, or that the drug has other pro-tumour side-effects in the xenograft setting that negate any beneficial effects.
The discrepancy between in vitro and in vivo results could be due to the experimental conditions being used. The xenografts, for example, were injected into flanks and may not represent the best possible model for studying behaviour of ovarian cancer in situ. Heparin could also help tumour growth by other means, for example, by inducing a higher degree of angiogenesis [86] . Results from other xenograft studies that investigated the effect of xenograft sensitivity to drugs appear to be at odds with our own data. In one study, both tinzaparin (a low-molecular weight heparin) and a non-anticoagulant heparin, S-NACH, decreased tumour growth and increased apoptosis in pancreatic cancer cells [87, 88] ; S-NACH also increased chemotherapy sensitivity in breast cancer xenografts [89] . Xenograft studies appear to suggest that heparin decreased tumour growth in lung cancer [90] and to confer sensitivity to gefitinib, a chemotherapeutic agent [91] . Another study revealed that heparin decreases cisplatin resistance of lung cancer cells [92] . However, other studies appear to suggest no benefit of adding heparin to conventional chemotherapy [93 -95] . The differences observed in these disparate studies may be down to subtle differences in methodology or the study model. Future experiments should be performed to ascertain the potential of heparin and other EV uptake inhibitors in sensitizing cancer cells to drug treatment.
Conclusion
Here we have demonstrated that EVs released following treatment of cells with a cisplatin are able to induce a range of effects in recipient cells. These include an adaptive response that yields greater resistance to drug treatment, and increased invasiveness. Blocking the transfer of EVs between cells may represent a means to sensitize tumours to chemotherapy, though further work is needed to establish whether these benefits can be translated to the in vivo setting. Future work is also needed to fully elucidate the pathways involved and how they contribute to tumour progression [96] . These data further highlight the importance of intercellular communication via EVs in the tumour microenvironment.
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